Cutibacterium avidum

(aka Propionibacterium avidum)

Bacteria
General | Carbohydrate O/F | Substrate utilisation | Enzymes | Metabolites | Antibiotics

Overview

  • Cutibacterium avidum, (aka Propionibacterium avidum), is a Gram-positive, non-spore-forming, anaerobic, non-motile, rod-shaped bacterium. It has been detected in at least 5 gut microbiome compilation studies or metastudies. Cutibacterium avidum is probably a rare gut coloniser. (Scholz2016)



  • This organism has been recovered from human skin, clinical sources (abscess, wound, tissue - CCUG) and human faeces. The risk classification (www.baua.de) for this organism is 2, i.e., risk of individual infection, but low risk of spread. It is an opportunistic pathogen. A possible gut commensal.
    • GENERAL CHARACTERISTICS (Scholz2016);
    Character Response
  • Substrates hydrolysed or digested:
  • gelatin;
  • ±
  • Strain-dependent hydrolysis or digestion:
  • milk;
  • H+
  • Acid from carbohydrates usually produced:
  • fructose; galactose; glucose; mannose; starch; maltose; melezitose; sucrose; trehalose; adonitol; erythritol; glycerol; inositol;
  • ±
  • Strain-dependent acid from carbs:
  • glycogen;
  • Active enzymes:
  • coagulase;
    • SPECIAL FEATURES
    Character Response
  • ✓
  • Metabolites produced:
  • H₂S;
  • ✗
  • Metabolites not produced:
  • indole;
  • ✗
  • Haemolysis:
  • absent
  • ✗
  • Nitrate:
  • not reduced
    • RESPONSE TO ANTIBIOTICS (Goldstein2003); (Tyrrell2012); (Snydman2008); (Goldstein2006d); (Goldstein2005); (Citron2003); (Goldstein2003a); (Goldstein2000); (Goldstein2000a);
    Class Active Resistant
  • Penicillins:
  • amoxicillin-clavulanic acid; ampicillin; ampicillin-sulbactam; doripenem; ertapenem; imipenem; meropenem; penicillin; penicillin G; piperacillin-tazobactam; ticarcillin-clavulanic acid;
  • Cephalosporins:
  • cefoxitin; cefuroxime;
  • Macrolides:
  • clarithromycin; erythromycin; pristinamycin; quinupristin-dalfopristin; telithromycin;
  • Tetracyclines:
  • doxycycline; minocycline;
  • Quinolines:
  • gatifloxacin; moxifloxacin;
  • Polypep/ketides:
  • bacitracin;
  • Heterocycles:
  • chloramphenicol;
  • co-trimoxazole; metronidazole;
  • Vancomycins:
  • vancomycin; dalbavancin; teicoplanin;
  • Miscellaneous antibiotics:
  • clindamycin; linezolid; pristinamycin; telithromycin;

  • Eggerth, A. H. (1935). The gram-positive non-spore-bearing anaerobic bacilli of human feces. Journal of Bacteriology, 30(3), 277–299.

    • Details

    GENERAL
    Lineage Physiology General Growth Tolerances Hydrol./digest./degr.
    Phylum:  Actinobacteria Class:  Actinomycetia Order:  Propionibacteriales Family:  Propionibacteriaceae Genus:  Cutibacterium Alt. name:  Propionibacterium avidum Gram stain:  + O2 Relation.:  anaerobic Spore:  No spore Motility:  Sessile Morphology:  Rod
    Health:  Unknown
    Source:  human skin, clinical sources (abscess, wound, tissue - CCUG) and human faeces
    		Gelatin:  + Milk:  curdle
    CARBOHYDRATE ACID FORMATION
    Monosaccharide O/F Oligosaccharide O/F Polysaccharide O/F Polyol O/F Other O/F
    Arabinose:  neg Fructose:  + Galactose:  + Glucose:  + Mannose:  + Rhamnose:  neg Xylose:  neg Cellubiose:  neg Lactose:  w Maltose:  + Melezitose:  + Sucrose:  + Trehalose:  + Amygdalin:  neg Aesculin:  neg Glycogen:  d Inulin:  w Starch:  + Adonitol:  + Dulcitol:  neg Erythritol:  + Glycerol:  + Inositol:  + Mannitol:  neg Sorbitol:  neg Me-α-D-Glc:  neg Me-α-D-Mann:  neg Salicin:  neg
    ENZYME ACTIVITY
    Enzymes: General Enzymes: Carbohydrate Enzymes: Protein Enzymes: Arylamidases Enzymes: Esters/fats
    Coagulase:  +
    METABOLITES - PRODUCTION & USE
    Fuel Usable Metabolites Metabolites Released Special Products Compounds Produced

    		H2S:  + Indole:  neg
    ANTIBIOTICS ℞
    Penicillins & Penems (μg/mL) Cephalosporins (μg/mL) Aminoglycosides (μg/mL) Macrolides (μg/mL) Quinolones (μg/mL)
    Augmentin:  S(MIC50): 0.125, MIC90: 0.5, RNG: (≤0.015-2)
    ampicillin:  S(MIC50): 0.125, MIC90: 0.125, RNG: (0.03-0.125)
    amp-sulb:  S(MIC50): 0.25, MIC90: 0.5, RNG: (0.06–0.25)
    penicillin:  S(MIC50): 0.06, MIC90: 0.125, RNG: (0.02-0.125)
    penicillin_G:  S(MIC50): 0.125, MIC90: 0.5, RNG: (≤0.03-1)
    piper-taz:  S(MIC50): 0.5, MIC90: 1, RNG: (≤0.03-1)
    tica-clav:  S(MIC50): 0.06, MIC90: 2, RNG: (0.06–4)
    doripenem:  S(MIC50): 0.06, MIC90: 0.06, RNG: (0.06–0.06)
    ertapenem:  S(MIC50): 0.06, MIC90: 0.25, RNG: (0.06–0.25)
    imipenem:  S(MIC50): 0.03, MIC90: 0.06, RNG: (≤0.015-0.06)
    meropenem:  S(MIC50): 0.06, MIC90: 0.25, RNG: (0.06–0.25)
    cefalexin:  Var(MIC50): 1, MIC90: >32, RNG: (0.25->32)
    cefoxitin:  S(MIC50): 0.25, MIC90: 2, RNG: (0.03–2)
    cefuroxime:  S(MIC50): 0.5, MIC90: 1, RNG: (0.25–8)
    azithromycin:  Var(MIC50): 0.06, MIC90: 8, RNG: (≤0.03->32)
    erythromycin:  S(MIC50): ≤0.03, MIC90: 2, RNG: (≤0.03-16)
    clarithromycin:  S(MIC50): 0.03, MIC90: 0.03, RNG: (0.03)
    pristinamycin:  S(MIC50): 0.03, MIC90: 0.03, RNG: (0.03)
    quin-dalf:  S(MIC50): 0.06, MIC90: 0.2, RNG: (0.06-0.25)
    telithromycin:  S(MIC50): 0.03, MIC90: 0.03, RNG: (0.03)
    linezolid:  S(MIC50): 0.5, MIC90: 1, RNG: (0.25-1)
    ciprofloxacin:  Var(MIC50): 1, MIC90: >8, RNG: (≤0.5->8)
    gatifloxacin:  S(MIC50): 0.125, MIC90: 0.25, RNG: (0.125–0.25)
    levofloxacin:  Var(MIC50): 0.5, MIC90: 8, RNG: (0.25-8)
    moxifloxacin:  S(MIC50): 0.25, MIC90: 0.5, RNG: (0.25–4)
    Tetracyclines (μg/mL) Vancomycin Class (μg/mL) Polypep/ketides (μg/mL) Heterocycles (μg/mL) Other (μg/mL)
    doxycycline:  S(MIC50): 0.25, MIC90: 0.5, RNG: (0.06–1)
    minocycline:  S(MIC50): 0.125, MIC90: 0.25, RNG: (0.06–1)
    tetracycline:  Var(MIC50): 1, MIC90: 16, RNG: (0.125-32)
    dalbavancin:  S(MIC50): 0.25, MIC90: 0.5, RNG: (0.03-0.5)
    teicoplanin:  S(MIC50): 0.5, MIC90: 1, RNG: (0.125–1)
    vancomycin:  S(MIC50): 0.5, MIC90: 0.5, RNG: (0.5-1)
    bacitracin:  S(MIC50): 0.25, MIC90: 4, RNG: (0.25–4)
    chloramphenicol:  S(MIC50): 1, MIC90: 2, RNG: (0.5–8)
    metronidazole:  R(MIC50): 32, MIC90: >32, RNG: (0.125->32)
    co-trimoxazole:  R(MIC50): >8, MIC90: >8, RNG: (4->8)
    clindamycin:  S(MIC50): ≤0.03, MIC90: 0.5, RNG: (≤0.03->32)
    daptomycin:  Var(MIC50): 2, MIC90: 2, RNG: (1-2)

    References

    SPECIFIC REFERENCES FOR CUTIBACTERIUM AVIDUM
  • Goldstein2003 - In Vitro Activities of Daptomycin, Vancomycin, Quinupristin- Dalfopristin, Linezolid, and Five Other Antimicrobials against 307 Gram-Positive Anaerobic and 31 Corynebacterium Clinical Isolates.
  • Scholz2016 - The natural history of cutaneous propionibacteria, and reclassification of selected species within the genus Propionibacterium to the proposed novel genera Acidipropionibacterium gen. nov., Cutibacterium gen. nov. and Pseudopropionibacterium gen. nov.
  • Cassir2015 - Clostridium butyricum Strains and Dysbiosis Linked to Necrotizing Enterocolitis in Preterm Neonates
  • Tyrrell2012 - In vitro activity of TD-1792, a multivalent glycopeptide-cephalosporin antibiotic, against 377 strains of anaerobic bacteria and 34 strains of Corynebacterium species.
  • Snydman2008 - In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
  • Goldstein2006d - Comparative in vitro activities of retapamulin (SB-275833) against 141 clinical isolates of Propionibacterium spp., including 117 P. acnes isolates.
  • Goldstein2005 - Comparative in vitro activities of XRP 2868, pristinamycin, quinupristin-dalfopristin, vancomycin, daptomycin, linezolid, clarithromycin, telithromycin, clindamycin, and ampicillin against anaerobic gram-positive species, actinomycetes, and lactobacilli.
  • Citron2003 - In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria.
  • Goldstein2003a - In vitro activities of ABT-492, a new fluoroquinolone, against 155 aerobic and 171 anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis.
  • Goldstein2000 - Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens.
  • Goldstein2000a - Comparative In vitro activities of ertapenem (MK-0826) against 1,001 anaerobes isolated from human intra-abdominal infections.
  • ...............................
    • GUT MICROBIOME COMPILATIONS AND METASTUDIES FOR CUTIBACTERIUM AVIDUM
  • Almeida2019 - A new genomic blueprint of the human gut microbiota.
  • Cassir2015 - Clostridium butyricum Strains and Dysbiosis Linked to Necrotizing Enterocolitis in Preterm Neonates
  • Forster2019 - A human gut bacterial genome and culture collection for improved metagenomic analyses.
  • Lagier2016 - Culture of previously uncultured members of the human gut microbiota by culturomics.
  • RajilicStojanovic2014 - The first 1000 cultured species of the human gastrointestinal microbiota.
  • ...............................
    • Added: April 08, 2021